Nifurtimox-Eflornithine Combination Therapy for Second-Stage Trypanosoma brucei gambiense Sleeping Sickness: A Randomized Clinical Trial in Congo | Zendy

Gérardo Priotto | Zendy; Saro Kasparian | Zendy; D Ngouama | Zendy; Sara Ghorashian | Zendy; Ute Arnold | Zendy; Salah Ghabri | Zendy; Unni Karunakara | Zendy

Open Access

Nifurtimox-Eflornithine Combination Therapy for Second-Stage Trypanosoma brucei gambiense Sleeping Sickness: A Randomized Clinical Trial in Congo

Author(s) -

Gérardo Priotto,

Saro Kasparian,

D Ngouama,

Sara Ghorashian,

Ute Arnold,

Salah Ghabri,

Unni Karunakara

Publication year - 2007

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/522982

Subject(s) - eflornithine , medicine , african trypanosomiasis , nifurtimox , trypanosomiasis , trypanosoma brucei , clinical trial , regimen , randomized controlled trial , virology , biology , parasite hosting , biochemistry , trypanosoma cruzi , world wide web , computer science , enzyme , spermidine , gene

Human African trypanosomiasis caused by Trypanosoma brucei gambiense is a fatal disease. Current treatment options for patients with second-stage disease are either highly toxic or impracticable in field conditions. We compared the efficacy and safety of the nifurtimox-eflornithine drug combination with the standard eflornithine regimen for the treatment of second-stage disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research